Improving oral vaccines by enhancing immune recognition of bacterial antigens
Boosting efficacy of oral vaccine candidates by enabling spore display of nitrated antigens
This study is exploring a new way to create better oral vaccines using a friendly bacterium to help your immune system recognize and fight off bacterial infections more effectively, which could lead to improved protection against diseases that don’t have good vaccines yet.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Delaware NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10472983 on NIH RePORTER |
What this research studies
This research focuses on developing more effective oral vaccines by using a bacterium called Bacillus subtilis to display specific antigens that can trigger a stronger immune response. The approach involves modifying the bacterium to present these antigens in a way that helps the immune system recognize and respond to bacterial infections more effectively. By using a novel amino acid modification, the researchers aim to enhance the immunogenicity of these antigens, making them more likely to activate immune cells. This could lead to better protection against bacterial diseases that currently lack effective vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of bacterial infections, particularly those in regions with limited access to effective vaccines.
Not a fit: Patients who are already immune to the targeted bacterial infections or those with specific contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against bacterial infections, potentially reducing the incidence of these diseases.
How similar studies have performed: Other research has shown promise in enhancing vaccine efficacy through similar immunogenic strategies, indicating potential for success in this novel approach.
Where this research is happening
Newark, UNITED STATES
- University of Delaware — Newark, United States (Active)
Researchers
- Principal investigator: Kunjapur, Aditya Mohan — University of Delaware
- Study coordinator: Kunjapur, Aditya Mohan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.